Criteria for Treatment: NCIWG

CAM211 Study Design

• Rai Stage III/IV

• Rai Stage 0-II (progressive)

  • Rapid doubling of peripheral lymphocyte count
  • Progressive lymphadenopathy and/or splenomegaly
  • B-symptoms
  • Others

Previous slide

Next slide

Back to first slide

View graphic version